In 1839, the harbors of Canton carried a strange irony. British merchants, draped in the banners of empire and commerce, argued that the flood of opium into China was nothing less than the noble work of “opening markets” and “facilitating trade.” Behind this polished rhetoric lay a darker truth: addiction was not an unintended side effect, but a calculated mechanism of profit. The more the Chinese population craved the drug, the more chests of silver poured into British coffers. When the Qing dynasty resisted, the British Navy enforced “free trade” with gunpowder and iron. Markets were opened, yes—but with cannon fire, not consent.
Fast forward nearly two centuries, across oceans and into the hills of Appalachia. The Sackler family, owners of Purdue Pharma, stood before doctors and regulators with the same polished vocabulary. Their product, OxyContin, they proclaimed, was a “medical breakthrough,” a humane answer to chronic pain. What they engineered, however, was not relief but dependency. They mapped human frailty as carefully as the British once mapped China’s rivers. Marketing campaigns saturated small towns, persuading doctors to prescribe liberally. Appalachia became ground zero, its families fractured by overdoses, its workforce hollowed by pills. Addiction was not a tragic byproduct—it was the business model.
The story of opium in 1839 and OxyContin in Appalachia is less about drugs than about the logic of empire and capital. In both cases, language softened the violence: “opening markets,” “medical breakthrough.” These phrases wrapped exploitation in the cloth of progress. Behind them, people became collateral, societies destabilized, and wealth flowed upwards. The parallels remind us that history does not repeat as much as it rhymes—new actors, new substances, but the same cold arithmetic: profit above people.
The Chinese scholar Lin Zexu, standing against British merchants in 1839, asked: “By what right do you flood our land with poison for profit?” Were he alive in Appalachia two hundred years later, he might ask the Sacklers the same.
Fast forward nearly two centuries, across oceans and into the hills of Appalachia. The Sackler family, owners of Purdue Pharma, stood before doctors and regulators with the same polished vocabulary. Their product, OxyContin, they proclaimed, was a “medical breakthrough,” a humane answer to chronic pain. What they engineered, however, was not relief but dependency. They mapped human frailty as carefully as the British once mapped China’s rivers. Marketing campaigns saturated small towns, persuading doctors to prescribe liberally. Appalachia became ground zero, its families fractured by overdoses, its workforce hollowed by pills. Addiction was not a tragic byproduct—it was the business model.
The story of opium in 1839 and OxyContin in Appalachia is less about drugs than about the logic of empire and capital. In both cases, language softened the violence: “opening markets,” “medical breakthrough.” These phrases wrapped exploitation in the cloth of progress. Behind them, people became collateral, societies destabilized, and wealth flowed upwards. The parallels remind us that history does not repeat as much as it rhymes—new actors, new substances, but the same cold arithmetic: profit above people.
The Chinese scholar Lin Zexu, standing against British merchants in 1839, asked: “By what right do you flood our land with poison for profit?” Were he alive in Appalachia two hundred years later, he might ask the Sacklers the same.
In 1839, the harbors of Canton carried a strange irony. British merchants, draped in the banners of empire and commerce, argued that the flood of opium into China was nothing less than the noble work of “opening markets” and “facilitating trade.” Behind this polished rhetoric lay a darker truth: addiction was not an unintended side effect, but a calculated mechanism of profit. The more the Chinese population craved the drug, the more chests of silver poured into British coffers. When the Qing dynasty resisted, the British Navy enforced “free trade” with gunpowder and iron. Markets were opened, yes—but with cannon fire, not consent.
Fast forward nearly two centuries, across oceans and into the hills of Appalachia. The Sackler family, owners of Purdue Pharma, stood before doctors and regulators with the same polished vocabulary. Their product, OxyContin, they proclaimed, was a “medical breakthrough,” a humane answer to chronic pain. What they engineered, however, was not relief but dependency. They mapped human frailty as carefully as the British once mapped China’s rivers. Marketing campaigns saturated small towns, persuading doctors to prescribe liberally. Appalachia became ground zero, its families fractured by overdoses, its workforce hollowed by pills. Addiction was not a tragic byproduct—it was the business model.
The story of opium in 1839 and OxyContin in Appalachia is less about drugs than about the logic of empire and capital. In both cases, language softened the violence: “opening markets,” “medical breakthrough.” These phrases wrapped exploitation in the cloth of progress. Behind them, people became collateral, societies destabilized, and wealth flowed upwards. The parallels remind us that history does not repeat as much as it rhymes—new actors, new substances, but the same cold arithmetic: profit above people.
The Chinese scholar Lin Zexu, standing against British merchants in 1839, asked: “By what right do you flood our land with poison for profit?” Were he alive in Appalachia two hundred years later, he might ask the Sacklers the same.
0 Kommentare
0 Anteile
224 Ansichten